Document and Entity Information - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Mar. 04, 2026 |
Jun. 30, 2025 |
|
| Document Document And Entity Information [Abstract] | |||
| Entity Registrant Name | ATEA PHARMACEUTICALS, INC. | ||
| Trading Symbol | AVIR | ||
| Entity Central Index Key | 0001593899 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Common Stock, Shares Outstanding | 79,672,083 | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Entity Small Business | true | ||
| Entity Shell Company | false | ||
| Entity Emerging Growth Company | false | ||
| Entity Current Reporting Status | Yes | ||
| Entity Tax Identification Number | 46-0574869 | ||
| Entity File Number | 001-39661 | ||
| Entity Address, Address Line One | 225 Franklin Street | ||
| Entity Address, Address Line Two | Suite 2100 | ||
| Entity Address, City or Town | Boston | ||
| Entity Address, State or Province | MA | ||
| Entity Address, Postal Zip Code | 02110 | ||
| City Area Code | 857 | ||
| Local Phone Number | 284-8891 | ||
| Entity Interactive Data Current | Yes | ||
| Title of 12(b) Security | Common Stock, $0.001 par value per share | ||
| Security Exchange Name | NASDAQ | ||
| Entity Incorporation, State or Country Code | DE | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Public Float | $ 262.6 | ||
| Entity Voluntary Filers | No | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Documents Incorporated by Reference | DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement for its 2026 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2025, are incorporated by reference into Part III of this Annual Report on Form 10-K. |
||
| Auditor Firm ID | 185 | ||
| Auditor Name | KPMG LLP | ||
| Auditor Location | Boston, Massachusetts | ||
| Auditor Opinion | Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of Atea Pharmaceuticals, Inc. and subsidiary (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. |